While simultaneous selective “targeted” delivery of gemcitabine by gemcitabine-(C4-amide)-[anti-EGFR] applied in dual-combination with gemcitabine-(C4-amide)-[anti-HER2/neu] can potentially improve the resolution of neoplastic disease states, such benefits would in part be made possible through reduction in innocent chemotherapeutic exposure by healthy tissues and normal organ systems. This evidence concerns the gene EGFR and neoplasm.